

Dr. Usmani Discusses Perseus, IsKia, Data Plus More Myeloma Updates
8 snips Dec 18, 2023
Dr. Saad Usmani, Chief of the Myeloma Service at the Memorial Sloan Kettering Cancer Center, discusses the evolution in myeloma treatment and highlights the Perseus and IsKia trials. The podcast also covers advancements in achieving MRD negativity, personalized therapy for translocation 1114 myeloma, autologous stem cell transplant, maintenance therapy, and mechanisms of resistance to BCMA and GPRC 5D directed therapies in myeloma.
Chapters
Transcript
Episode notes
1 2 3 4 5 6
Introduction
00:00 • 2min
Advancements in Myeloma Treatment and the Shift towards MRD Negativity
01:51 • 13min
Discussion on Venetoclax Data and Personalizing Therapy for Translocation 1114 Myeloma
14:34 • 2min
Autologous Stem Cell Transplant in Newly Diagnosed Myeloma
17:03 • 2min
Maintenance Therapy in the Treatment of Myeloma
18:47 • 6min
Mechanisms of Resistance to BCMA and GPRC 5D Directed Therapies in Myeloma
25:09 • 2min